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Introduction
Premenstrual syndrome (PMS) is the cyclic appearance
of one or more of a group of symptoms just before each
menses, to a degree that can affect the sufferer’s qual-
ity of life. The most frequent symptoms include abdom-
inal bloating, breast tenderness, anxiety, crying spells,
depression, fatigue, lack of energy, anger and irritability,
changes in appetite, and varying degrees of edema [1].
The prevalence of PMS during the reproductive
period has been reported to be between 70% and 90%
[2]. Diagnosis requires the presence of at least one
symptom of somatic or mood disorders occurring 
during 3 consecutive months, beginning during the last
week of each cycle and interfering with work or usual
activities, and remitting after each menses [3]. Based
on a study performed in 2004 [4], women with PMS had
more work absences than those without PMS (7.3 vs. 2.5
days; p = 0.006). Women with PMS also had more days
of disturbances during their school work or jobs com-
pared with those without PMS [4].
Thys-Jacobs et al [2] demonstrated a relationship
between hypocalcemia and PMS symptoms, including
fatigue, anxiety, depression, mood changes, and mus-
cle cramps. They suggested that PMS symptoms were
equivalent to signs of osteoporosis during menopause.
Shamberger [5] revealed that levels of calcium and
some trace elements in red blood cells were lower than
normal in women with PMS. A relationship between
intracellular calcium concentration and mood disorders
in PMS has been demonstrated during the last 50 years
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[6]. Changes in extracellular calcium concentration
could have stimulatory effects on neuromuscular junc-
tions [7], and irritability, mania and agitation have been
reported in conjunction with hypocalcemia [8]. Based
on these observations, we evaluated the efficacy of
500 mg of calcium carbonate twice a day for 3 months
on reduction of PMS symptoms.
Materials and Methods
This randomized, double-blind clinical trial was per-
formed during 2005. We selected female college students
who were living in the dormitory of Tehran Medical
University. Exclusion criteria were any kind of physical
or psychologic disorder included in the differential diag-
nosis of PMS, including depressive disorders, anxiety
and panic disorders, migraine headache, irritable bowel
syndrome, asthma, chronic fatigue syndrome, thyroid
and adrenal disorders, and the use of any medication
or multivitamins. Five hundred students filled out a
primary questionnaire. Of these, 260 met the criteria
for PMS and were enrolled in this study. Some failed to
complete the study and were excluded, leaving a total
of 179 students. After obtaining written legal and moral
consent, they were randomly divided into two groups.
There were 88 students in Group A and 91 in Group B.
One group (blindly) received 3 months of treatment
with 500 mg of calcium carbonate twice a day while
the other group received a placebo. Both placebo and
calcium carbonate were produced by the pharmaceu-
tical company, Tehran Chimi, Iran. Both groups were
given their medication or placebo by a medical trainee,
and they were contacted each week during the study to
encourage them to continue their medication. At the
end of the treatment period, they filled out a second
questionnaire to evaluate changes in the intensity of their
symptoms. Both the initial and the second question-
naires were designed based on the Beck test, and the
intensity of the symptoms was scored from 0 to 3. The
data were analyzed with χ2 test, t test, paired t test,
and McNemar test, using SPSS version 11 (SPSS Inc.,
Chicago, IL, USA).
The PMS symptoms evaluated included breast 
tenderness, fatigue, lack of energy, appetite changes,
sleep problems, headache, depression, agitation, and
irritability.
Results
At the end of the study, the company revealed that
Group A had received the placebo and Group B had
received the calcium tablets. The mean age for both
groups was the same (21.4 ± 3.6 years). All physical and
psychologic symptoms were similar in both groups
(Table 1).
Before treatment, 47.7% of the women in Group A
and 57.1% in Group B suffered from breast tenderness
(p = 0.20; Table 1). After treatment, these values were
51.1% in Group A and 57.1% in Group B (p = 0.42;
Table 2).
Before treatment, 60.5% of Group A and 72.2% in
Group B suffered from early tiredness. After treatment,
the incidence of early tiredness fell to 52.3% in Group
A, and 36.0% in Group B (p = 0.029; Table 3). The
McNemar test revealed that the incidence of early
tiredness was significantly reduced in Group B after
treatment (from 72.2% to 36.0%; p < 0.001), while the
incidence in Group A showed no significant reduction
(p = 0.37).
Lack of appetite was observed in 81.8% of women
in Group A and 77.0% in Group B before intervention
(p = 0.370; Table 1). After treatment, lack of appetite
was found in 75.0% of women in Group A and 52.7%
in Group B (p = 0.004; Table 2). These results suggest
that the treatment in Group B was more effective than
that in Group A.
The incidence of premenstrual headache was similar
in both groups before treatment (Table 1), and there
was no significant change after treatment in either group
(p = 0.66; Table 2).
Before treatment, anxiety and agitation were ob-
served in 61 women (70.9%) in Group A and 63 (69.2%)
in Group B. After treatment, 68.6% in Group A and
65.2% in Group B still suffered from this symptom
(p = 0.62; Table 2), suggesting no effect of the inter-
vention on anxiety and agitation.
As shown in Table 1, irritability was observed in
80.2% of women in Group A and 87.9% in Group B
before treatment. After treatment, these were reduced
to 54.7% in Group A and to 42.7% in Group B. Com-
parison between the two groups after treatment re-
vealed no significant difference, but the McNemar test
showed a meaningful reduction in incidence (25.5% in
Group A and 45.2% in Group B) following treatment
in both groups, suggesting that both calcium and
placebo effectively reduced irritability (Table 2).
There were no significant differences in sleep pat-
terns (insomnia, hypersomnia or hyposomnia) before
(Table 1) and after treatment (Table 2).
Lack of energy before each menses was experienced
by 60.5% of women in Group A and 60.4% in Group B
(Table 1). After intervention, 34.9% in Group A and
32.2% in Group B still showed this symptom. There was
no significant difference between the groups (p = 0.7;
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Table 2), but the reductions within each group were
both significant (p = 0.002 for Group A and p = 0.001
for Group B). As for irritability, both placebo and cal-
cium reduced the incidence of lack of energy in women
with PMS.
Before intervention, the incidence of sadness and
depression was similar in both groups (74.4% in Group
A and 70.3% in Group B; Table 1). The McNemar test
revealed a 17.4% reduction in Group A and a 37.1%
reduction in Group B. The reduction in Group B was
statistically significant (p = 0.0001; Table 4).
Based on the results of the questionnaire, the average
baseline scores for intensity of psychologic symptoms
were 6.59±3.60 in Group A and 7.26±3.82 in Group B.
After the study, the average scores were 5.85 ± 3.84 in
Group A and 6.02 ± 3.68 in Group B. Using t test, the
reduction of 16.3% in the average score in Group B was
significant (p = 0.01), while the reduction in symptoms
in Group A was not significant (p = 0.16).
Discussion
Similar studies have been performed by Thys-Jacobs et al
[9] in 1989 using 33 cases, by Penland and Johnson
[10] in 1993 with 10 cases, and by Bertone-Johnson 
et al [11] in 2005 with 1,968 cases. We performed a
double-blind clinical trial involving 179 female college
students. Comparison of the results before and after
intervention revealed that depression and sadness
were reduced significantly more in the women receiv-
ing calcium (27%) than in those receiving placebo
(7%) (p < 0.002). These results were similar to those
from the study of Penland and Johnson [10]. They
showed that calcium supplements alleviated concentra-
tion problems and affective and behavioral variations
related to PMS (p = 0.01). Thys-Jacobs [12] reported 
a 45% reduction in mood disorders and depressive
symptoms in women receiving calcium supplements,
compared with 28% in the placebo group. Bohrer and
Table 1. Frequency distribution of qualitative variables in Groups A and B before treatment*
Group variables Group A Group B p†
Breast tenderness 0.20
Yes 42/88 (47.7) 52/91 (57.1)
No 46/88 (52.3) 39/91 (42.9)
Early tiredness 0.099
Yes 52/86 (60.5) 65/90 (72.2)
No 34/86 (39.5) 25/90 (27.8)
Appetite 0.370
Normal 8/88 (9.1) 10/87 (11.5)
Less 72/88 (81.8) 67/87 (77.0)
More 8/88 (9.1) 10/87 (11.5)
Headache 0.665
Yes 33/88 (37.5) 37/91 (40.7)
No 55/88 (62.5) 54/91 (59.3)
Anxiety 0.805
Yes 61/86 (70.9) 63/91 (69.2)
No 25/86 (29.1) 28/91 (30.8)
Irritability
Yes 69/86 (80.2) 80/91 (87.9)
No 17/86 (19.8) 11/91 (12.1)
Sleep pattern changes 0.579
Yes 48/86 (55.8) 47/91 (51.6)
No 38/86 (44.2) 44/91 (48.4)
Lack of energy 0.997
Yes 52/86 (60.5) 55/91 (60.4)
No 34/86 (39.5) 36/91 (39.6)
Depression and sadness 0.543
Yes 64/86 (74.4) 64/91 (70.3)
No 22/86 (25.6) 27/91 (29.7)
*Data are presented as n (%); †statistical significance assessed using the χ2 test.
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Krannich [13] found that calcium supplements effec-
tively reduced depressive symptoms (p = 0.045).
Overall, the results of these studies suggest that
treatment with calcium supplements is an effective
method for reducing mood disorders during PMS. How-
ever, calcium had no effect on the incidence of breast
tenderness in this study (p = 0.42), which is in accor-
dance with the results of the study by Penland and
Johnson [10]. The incidence of tiredness was reduced
(p < 0.001), which was again in agreement with the
results of Penland and Johnson [10] that showed a
reduced incidence of early tiredness following calcium
Table 2. Frequency distribution of qualitative variables in Groups A and B after treatment*
Group variables Group A Group B p†
Breast tenderness 0.42
Yes 45/88 (51.1) 52/91 (57.1)
No 43/88 (48.9) 39/91 (42.9)
Early tiredness 0.029‡
Yes 45/86 (52.3) 32/89 (36.0)
No 41/86 (47.7) 57/89 (64.0)
Appetite 0.004‡
Normal 11/88 (12.5) 15/91 (16.5)
Less 66/88 (75.0) 48/91 (52.7)
More 11/88 (12.5) 28/91 (30.8)
Headache 0.66
Yes 33/88 (37.5) 37/91 (40.7)
No 55/88 (62.5) 54/91 (59.3)
Anxiety 0.62
Yes 59/86 (68.6) 58/89 (65.2)
No 27/86 (31.4) 31/89 (34.8)
Irritability 0.11
Yes 47/86 (54.7) 38/89 (42.7)
No 39/86 (45.3) 51/89 (57.3)
Sleep changes 0.99
Yes 40/85 (47.1) 50/90 (55.6)
No 45/85 (52.9) 40/90 (44.4)
Lack of energy 0.7
Yes 30/86 (34.9) 29/90 (32.2)
No 56/86 (65.1) 61/90 (67.8)
Depression and sadness 0.002‡
Yes 58/86 (67.4) 39/89 (43.8)
No 28/86 (32.6) 50/89 (56.2)
*Data are presented as n (%); †statistical significance assessed using the χ2 test; ‡significant.
Table 3. Frequency distribution of early tiredness before and after treatment in Groups A and B*
Tiredness Tiredness after treatment
Variables
before treatment No Yes Total
p†
Group A No 15 (17.4) 19 (22.1) 34 (39.5) 0.37
Yes 26 (30.2) 26 (30.2) 52 (60.5)
Total 41 (47.7) 45 (52.3) 86 (100)
Group B‡ No 19 (21.1) 6 (6.7) 25 (27.8) 0.001
Yes 38 (42.2) 27 (30.0) 65 (72.2)
Total 57 (63.3) 33 (36.7) 90 (100)
*Data are presented as n (%); †statistical significance assessed using the McNemar test; ‡of the respondents before treatment, one did not answer the question
after treatment.
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supplementation (p < 0.05). Early tiredness and depres-
sion can be considered as two related symptoms, and
any treatment that reduces depression will also cause
improvements in early tiredness.
Both groups experienced improvements in appetite
after treatment, but the improvement was greater in
the calcium group (p = 0.004). Although the study of
Alvir and Thys-Jacobs [14] demonstrated an apparent
change in appetite disorders after administering cal-
cium treatment for PMS symptoms, Lorenzen et al [15]
failed to find any effect of calcium therapy on appetite
disorders during PMS. Our findings suggest a possible
relationship between mood disorders and appetite
changes during PMS, but further studies are needed to
confirm this hypothesis.
We found no significant effect of calcium therapy
on headache, though Thys-Jacobs et al [2] and Penland
and Johnson [10] found a positive effect of calcium
treatment. This discrepancy may be due to differences
in sample size. There was no improvements in anxiety in
either group, but irritability was significantly reduced
in both groups (both p<0.001), suggesting that placebo,
as well as calcium, also reduced irritability. However,
the study by Thys-Jacobs et al [2] showed a 50% reduc-
tion in irritability symptoms after treatment with cal-
cium compared with those who received placebo. The
study of Thys-Jacobs in 2000 also revealed an effective
improvement in mood disorders and irritability after
treatment [12].
In this study, treatment had no significant effect 
on sleep disorders in Group A and Group B (p = 0.74
and 0.34, respectively). In the study by Thys-Jacobs in
2000, however, there was a significant improvement in
sleep disorders after treatment [12]. Again, this discrep-
ancy may be due to differences in treatment duration,
calcium dose or the number of cases. Larger studies
are needed to clarify this relationship.
In a double-blind clinical trial involving 441 cases,
improvements in physical and psychologic symptoms
were observed in 48% of women who used calcium
supplements, compared with only 30% in the placebo
group [2]. In the current study, a general improvement
in physical and psychologic symptoms was observed in
about 36% of patients receiving calcium, compared with
only 29% receiving placebo.
An association between cyclic calcium changes and
mood instability during each menstrual cycle has pre-
viously been reported in women with PMS [16]. An asso-
ciation between hypoparathyroidism and hypocalcemia
as an aggravating factor in women with depressive symp-
toms has also been demonstrated [13]. Evidence for
an association between secondary hyperparathyroidism
and PMS symptoms, and for improvement of symptoms
after calcium treatment shows the importance of cal-
cium supplements [17]. Although there was a significant
reduction in depressive symptoms after treatment, we
did not measure serum calcium concentration and so
were unable to prove this relationship.
In conclusion, the results of this study demonstrated
that PMS symptoms of early tiredness, appetite changes,
and depression were significantly improved by calcium
treatment. This study, together with others [18–20],
suggests that calcium therapy is a safe, effective and
convenient method for reducing the intensity and fre-
quency of PMS symptoms, with consequent improve-
ments in quality of life.
Acknowledgments
This study resulted from a research program approved
by the Tehran University of Medical Sciences and ValiAsr
Reproductive Health Research Center.
References
1. Speroff L. Menstrual disorders. In: Speroff L, Glass R, Kase N,
eds. Clinical Gynecologic Endocrinology and Infertility, 6th edition.
Baltimore: Lippincott Williams & Wilkins, 1999:557–8.
Table 4. Frequency distribution of depression before and after treatment in Groups A and B*
Depression Depression after treatment
Variables
before treatment No Yes Total
p†
Group A No 13 (15.1) 9 (10.5) 22 (25.6) 0.30
Yes 15 (17.4) 49 (57.0) 64 (74.4)
Total 28 (32.6) 58 (67.4) 86 (100)
Group B No 17 (19.1) 9 (10.1) 26 (29.2) 0.0001
Yes 33 (37.1) 30 (33.7) 63 (70.8)
Total 50 (56.2) 39 (43.8) 89 (100)
*Data are presented as n (%); †statistical significance assessed using the McNemar test.
Taiwan J Obstet Gynecol • June 2009 • Vol 48 • No 2 129
Calcium and PMS
2. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium car-
bonate and the premenstrual syndrome: effects on premen-
strual and menstrual symptoms. Am J Obstet Gynecol 1998;
179:444–52.
3. Yazdi  A. The premenstrual syndrome. J Fertil Infertil Assoc
2003;2:21–3.
4. Dean BB, Borenstein JE. A prospective assessment investigat-
ing the relationship between work productivity and impair-
ment with premenstrual syndrome. J Occup Environ Med 2004;
46:649–56.
5. Shamberger RJ. Calcium, magnesium, and other elements
in the red blood cells and hair of normals and patients with
premenstrual syndrome. Biol Trace Elem Res 2003;94:123–9.
6. Weston PG, Howard MQ. The determination of sodium,
potassium, calcium and magnesium in the blood and spinal
fluid of patients suffering from manic depressive insanity.
Arch Neurol Psychiatry 1992;8:179–83.
7. Carman JS, Crews E, Bancroft A, et al. Calcium and calcium
regulating hormones in the biphasic periodic psychoses. 
J Oper Psychiatry 1980;11:5–17.
8. Jimerson DC, Post RM, Carman JS, van Kammen DP, Wood
JH, Goodwin FK, Bunney WE Jr. CSF calcium: clinical corre-
lates in affective illness and schizophrenia. Biol Psychiatry
1979;14:37–51.
9. Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA,
Alvir J. Calcium supplementation in premenstrual syndrome:
a randomized crossover trial. J Gen Intern Med 1989;4:183–9.
10. Penland JG, Johnson PE. Dietary calcium and manganese
effects on menstrual cycle symptoms. Am J Obstet Gynecol
1993;168:1417–23.
11. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR,
Willett WC, Manson JE. Calcium and vitamin D intake and 
risk of incident premenstrual syndrome. Arch Intern Med
2005;165:1246–52.
12. Thys-Jacobs S. Micronutrients and the premenstrual 
syndrome: the case for calcium. J Am Coll Nutr 2000;19:
220–7.
13. Bohrer T, Krannich JH. Depression as a manifestation of
latent chronic hypoparathyroidism. World J Biol Psychiatry
2007;8:56–9.
14. Alvir JM, Thys-Jacobs S. Premenstrual and menstrual symptom
clusters and response to calcium treatment. Psychopharmacol
Bull 1991;27:145–8.
15. Lorenzen JK, Nielsen S, Holst JJ, Tetens I, Rehfeld JF, Astrup
A. Effect of dairy calcium or supplementary calcium intake
on postprandial fat metabolism, appetite, and subsequent
energy intake. Am J Clin Nutr 2007;85:678–87.
16. Thys-Jacobs S, McMahon D, Bilezikian JP. Cyclical changes
in calcium metabolism across the menstrual cycle in women
with premenstrual dysphoric disorder. J Clin Endocrinol Metab
2007;92:2952–9.
17. Thys-Jacobs S, Alvir MY. Calcium-regulating hormones across
the menstrual cycle: evidence of a secondary hyperparathy-
roidism in women with PMS. J Clin Endocrinol Metab 1995;
80:2227–32.
18. Zaafrane F, Faleh R, Melki W, Sakouhi M, Gaha L. 
An overview of premenstrual syndrome. J Gynecol Obstet Biol
Reprod (Paris) 2007;36:642–52. [In French]
19. Frackiewicz EJ, Shiovitz TM. Evaluation and management
of premenstrual syndrome and premenstrual dysphoric 
disorder. J Am Pharm Assoc (Wash) 2001;41:437–47.
20. Rapkin AJ, Mikacich JA. Premenstrual syndrome in adoles-
cents: diagnosis and treatment. Pediatr Endocrinol Rev 2006;
3(Suppl 1):132–7.
